When managing side effects from highly effective therapies like MEK inhibitors, it's often better to temporarily hold treatment and then resume at the original dose rather than immediately dose-reducing. This strategy maintains dose intensity, which is critical for maximizing the drug's therapeutic benefit.

To improve long-term tolerability of amivantamab, some experts advocate for a "marathon, not a sprint" approach. This involves aggressive dose holds or reductions at the earliest signs of toxicity, even low-grade, to prevent side effects from escalating and ensure patients can remain on effective therapy longer.

For patients with significant comorbidities like cardiovascular disease, proactively starting lenvatinib at a reduced dose (e.g., 14mg instead of 20mg) is a practical strategy to mitigate anticipated severe toxicities from the outset.

To manage infection risk and improve quality of life, experts are quickly reducing bispecific antibody dosing frequency (e.g., to monthly) once a response is achieved. This real-world practice deviates from rigid trial schedules to optimize patient outcomes.

Clinicians emphasize that maintaining treatment continuity with a reduced, tolerable chemotherapy dose is superior to discontinuing therapy due to side effects. This approach helps patients stay on treatment longer, potentially improving overall survival.

To prevent irreversible toxicities like neuropathy from enfortumab vedotin, clinicians should proactively set expectations. Emphasize that dose adjustments are normal and part of a long-term strategy. Framing it as a "marathon, not a sprint" encourages patients to report side effects early, rather than hiding them for fear of stopping treatment.

The classic study suggesting >90% adherence is necessary for CML response is outdated. Modern practice shows that controlled dose reductions to improve tolerability can actually lead to better overall outcomes, challenging the idea that perfect adherence to the initial prescribed dose is paramount.

A majority of patients on the lenvatinib/pembrolizumab regimen require dose reductions due to toxicity. Crucially, clinical trial data shows no significant change in progression-free survival for patients on lower doses, an important point for patient reassurance.

Clinicians recommend starting lenvatinib at the full 20mg dose rather than escalating from a lower dose. This ensures therapeutic levels are reached. They then dose-reduce aggressively as needed. Starting low risks falsely concluding the drug is ineffective if the patient tolerates a suboptimal dose without response.